Experimental Hematology
Volume 38, Issue 5 , Pages 392-402.e1 , May 2010

Tyrosine phosphorylation of SHIP promotes its proteasomal degradation

  • Jens Ruschmann

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • Fachbereich Biologie, Chemie, Pharmazie, Freie Universität-Berlin, Berlin, Germany
    • ,
  • Victor Ho

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Frann Antignano

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Etsushi Kuroda

      Affiliations

    • Department of Immunology and Parasitology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan
    • ,
  • Vivian Lam

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Mariko Ibaraki

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Kim Snyder

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Connie Kim

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Richard A. Flavell

      Affiliations

    • Department of Immunobiology, Yale University, School of Medicine and the Howard Hughes Medical Institute, New Haven, Conn., USA
    • ,
  • Toshiaki Kawakami

      Affiliations

    • Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, Calif., USA
    • ,
  • Laura Sly

      Affiliations

    • Department of Pediatrics, Division of Gastroenterology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
    • ,
  • Ali G. Turhan

      Affiliations

    • NSERM U935, Université de Poitiers and Service d'Hématologie et d'Oncologie Biologique, CHU de Poitiers, Poitiers, France
    • ,
  • Gerald Krystal

      Affiliations

    • The Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    • Corresponding Author InformationOffprint requests to: Gerald Krystal, Ph.D., The Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

Received 2 March 2010 ,Revised 2 March 2010 ,Accepted 8 March 2010.

References 

  1. Antignano F, Ruschmann J, Hamilton M, et al. The Src homology 2 containing inositol 5' phosphatases. In:  Bradsaw RA,  Dennis EA editor. Handbook of Cell Signalling. San Diego: Elsevier Inc; 2009;p. 1065–1084
  2. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity. 2004;21:227–239
  3. Sly LM, Hamilton MJ, Kuroda E, et al. SHIP prevents lipopolysaccharide from triggering an anti-viral response in mice. Blood. 2009;113:2945–2954
  4. Sattler M, Salgia R, Shrikhande G, et al. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997;15:2379–2384
  5. Sattler M, Verma S, Byrne CH, et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999;19:7473–7480
  6. Damen JE, Liu L, Ware MD, Ermolaeva M, Majerus PW, Krystal G. Multiple forms of SHIP are generated by C-terminal truncation. Blood. 1998;92:1199–1205
  7. Gardai S, Whitlock BB, Helgason C, et al. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002;277:5236–5246
  8. Malbec O, Attal JP, Fridman WH, Daeron M. Negative regulation of mast cell proliferation by FcγRIIB. Mol Immunol. 2002;38:1295–1299
  9. Hibbs ML, Harder KW, Armes J, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002;196:1593–1604
  10. Baran CP, Tridandapani S, Helgason CD, Humphries RK, Krystal G, Marsh CB. The inositol 5'-phosphatase SHIP-1 and the Src kinase lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem. 2003;278:38628–38636
  11. Harder KW, Quilici C, Naik E, et al. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. Blood. 2004;104:3901–3910
  12. Hernandez-Hansen V, Smith AJ, Surviladze Z, et al. Dysregulated FcγRI signaling and altered Fyn and SHIP activities in Lyn-deficient mast cells. J Immunol. 2004;173:100–112
  13. Xiao W, Nishimoto H, Hong H, et al. Positive and negative regulation of mast cell activation by Lyn via the FcγRI. J Immunol. 2005;175:6885–6892
  14. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem. 2003;278:4847–4853
  15. Jagani Z, Song K, Kutok JL, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res. 2009;69:6546–6555
  16. Crawford LJ, Windrum P, Magill L, et al. Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol. 2009;37:357–366
  17. Magill L, Lynas J, Morris TC, Walker B, Irvine AE. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Haematologica. 2004;89:1428–1433
  18. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003;88:853–863
  19. Tauchi T, Yoshimura A, Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. Exp Hematol. 2001;29:356–361
  20. Dou QP, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther. 1999;289:781–790
  21. Dai Z, Quackenbush RC, Courtney KD, et al. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 1998;12:1415–1424
  22. Kojima M, Oguro K, Sawabe K, et al. Rapid turnover of tryptophan hydroxylase is driven by proteasomes in RBL2H3 cells, a serotonin producing mast cell line. J Biochem. 2000;127:121–127
  23. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56 lyn and p59 hck by p210 bcr/abl in myeloid cells. Cancer Res. 1996;56:3589–3596
  24. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem. 1997;272:33260–33270
  25. Lionberger JM, Wilson MB, Smithgall TE. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem. 2000;275:18581–18585
  26. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002;21:8075–8088
  27. Brehme M, Hantschel O, Colinge J, et al. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A. 2009;106:7414–7419
  28. Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996;380:627–630
  29. Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T. Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest. 2008;118:924–934
  30. Chari R, Kim S, Murugappan S, Sanjay A, Daniel JL, Kunapuli SP. Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion. Blood. 2009;114:3056–3063
  31. Xu R, Abramson J, Fridkin M, Pecht I. SH2 domain-containing inositol polyphosphate 5'-phosphatase is the main mediator of the inhibitory action of the mast cell function-associated antigen. J Immunol. 2001;167:6394–6402
  32. Ptasznik A, Urbanowska E, Chinta S, et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J Exp Med. 2002;196:667–678
  33. Backers K, Blero D, Paternotte N, Zhang J, Erneux C. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv Enzyme Regul. 2003;43:15–28
  34. Schnupf P, Portnoy DA, Decatur AL. Phosphorylation, ubiquitination and degradation of listeriolysin O in mammalian cells: role of the PEST-like sequence. Cell Microbiol. 2006;8:353–364
  35. Leu TH, Charoenfuprasert S, Yen CK, Fan CW, Maa MC. Lipopolysaccharide-induced c-Src expression plays a role in nitric oxide and TNFalpha secretion in macrophages. Mol Immunol. 2006;43:308–316
  36. Giuriato S, Bodin S, Erneux C, et al. pp60c-src associates with the SH2-containing inositol-5-phosphatase SHIP1 and is involved in its tyrosine phosphorylation downstream of αIIbβ3 integrin in human platelets. Biochem J. 2000;348:107–112
  37. Cao L, Yu K, Banh C, et al. Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol. 2007;179:5864–5876
  38. DiNitto JP, Lambright DG. Membrane and juxtamembrane targeting by PH and PTB domains. Biochim Biophys Acta. 2006;1761:850–867
  39. Dugray A, Geay JF, Foudi A, et al. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia. 2001;15:1658–1662

PII: S0301-472X(10)00101-3

doi: 10.1016/j.exphem.2010.03.010

Experimental Hematology
Volume 38, Issue 5 , Pages 392-402.e1 , May 2010

Article Tools

* Image Usage & Resolution